Femasys Inc.
Femasys is a biomedical company developing minimally invasive, in-office technologies for women's reproductive health, including fertility and permanent birth control solutions.
About
Femasys Inc. (Nasdaq: FEMY) is a biomedical innovator focused on transforming women's reproductive healthcare. The company develops and commercializes a suite of product candidates, including minimally invasive, in-office technologies for fertility treatment and permanent birth control, as well as diagnostic tools.
Key facts
At-a-glance profile data
- Website
- femasys.com
- Headquarters
- Suwanee, United States
- Founded
- 2004
- Total funding
- $34M (IPO)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 16 Jun 2021 | IPO | $34M | Chardan Capital Markets, JonesTrading Institutional Services LLC |
Tech stack
Detected on femasys.com, last scanned 21 Aug 2026. Run your own scan
- Frontend
- Tailwind CSS, Bootstrap
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Barracuda
Frequently asked
What does Femasys Inc. do?
Their solutions aim to expand access to care, improve outcomes, and reduce costs for women worldwide.
What is Femasys Inc.'s Effective Domain Rating?
StartupHub's Effective Domain Rating for Femasys Inc. is 54 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is underrated against its Ahrefs Domain Rating of 39, meaning it surfaces in search and AI results more than its claimed authority alone would suggest.
Is Femasys Inc. trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Femasys Inc. is 71 out of 100, based on site security posture and privacy practices.
How much funding has Femasys Inc. raised?
Femasys Inc. has raised a total of $34M in funding. The most recent round on record is IPO.